Literature DB >> 35957767

Suprachoroidal hemorrhage during phacoemulsification surgery associated with recent COVID-19: A report of two cases.

Hossein Jamali1, Elham Sadeghi1, Mohammad Hossein Nowroozzadeh1.   

Abstract

To report two cases of suprachoroidal hemorrhage during otherwise uncomplicated phacoemulsification, in whom COVID-19 was documented with a positive PCR test about 1 month before the surgery and the importance of postponing elective surgeries for several months after infection.
© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  COVID‐19; case report; cataract surgery; phacoemulsification; suprachoroidal hemorrhage

Year:  2022        PMID: 35957767      PMCID: PMC9361714          DOI: 10.1002/ccr3.6204

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN: 2050-0904


INTRODUCTION

Suprachoroidal hemorrhage (SCH) is a rare complication of intraocular surgery that could be devastating and associated with permanent visual loss in some cases. The reported incidence of SCH during cataract surgery is 0.03–0.13%, usually occurring in patients with known systemic and ocular risk factors. Angiotensin‐converting enzyme 2 is a receptor for SARS‐CoV‐2 and is highly expressed in ocular vascular endothelial cells. The choroid is the most densely vascularized tissue in the body. Herein, we present two cases with a recent history of COVID‐19 who developed SCH during uncomplicated phacoemulsification surgery.

CASE PRESENTATION

Case 1

The first case was a 60‐year‐old man who underwent planned phacoemulsification cataract surgery in the left eye. His medical history was unremarkable. The patient had a documented positive polymerase‐chain‐reaction (PCR) for COVID‐19 5 weeks before the operation when he developed fever, cough, and body pain for a couple of weeks. The baseline characteristics of the patient are summarized in Table 1.
TABLE 1

Characteristics of the two patients with recent COVID‐19 and suprachoroidal hemorrhage during planned phacoemulsification.

Case 1Case 2
Age, years6071
GenderMaleFemale
Systemic diseaseNoneGrade‐1 hypertension
EyeLeftRight
BCVA20/200Light perception
IOP, mmHg1514
Slit‐lamp exam3+ nuclear cataractMature cataract
FundoscopyNormalImpossible a
Anterior chamber depth, mm3.413.23
Axial length, mm23.323.4
Intraoperative heart rate, (mean, maximum), bpm(67, 75)(122, 130)
Intraoperative systolic BP, (mean, maximum), mmHg(75, 84)(128, 140)

Abbreviations: BCVA, best‐corrected visual acuity; BP, blood pressure; bpm, beats per minute.

Preoperative B‐scan sonography showed attached retina and choroid with clear vitreous.

Characteristics of the two patients with recent COVID‐19 and suprachoroidal hemorrhage during planned phacoemulsification. Abbreviations: BCVA, best‐corrected visual acuity; BP, blood pressure; bpm, beats per minute. Preoperative B‐scan sonography showed attached retina and choroid with clear vitreous. The operation was uneventful till the irrigation/aspiration phase, when the anterior chamber suddenly became flattened, the posterior capsule attached to the cornea, and the iris prolapsed from the main incision. Intraoperative indirect ophthalmoscopy revealed temporal choroidal hemorrhage without the involvement of the posterior pole. The main corneal incision was sutured, and IOL insertion was postponed after the complete resorption of choroidal hemorrhage. The SCH was resolved within 4 weeks without any significant sequel (Figure 1). After the second surgery for IOL implantation, the final visual acuity returned to 20/20.
FIGURE 1

Left, the B‐scan ocular ultrasound image of Case 1 obtained 2 days after the surgery indicating the area of the suprachoroidal hemorrhage (between arrows). Right, EDI‐OCT image of the same patient took 3 weeks after the operation, showing normal macula with a subfoveal choroidal thickening.

Left, the B‐scan ocular ultrasound image of Case 1 obtained 2 days after the surgery indicating the area of the suprachoroidal hemorrhage (between arrows). Right, EDI‐OCT image of the same patient took 3 weeks after the operation, showing normal macula with a subfoveal choroidal thickening.

Case 2

The second case was a 71‐year‐old woman (Table 1) who underwent planned phacoemulsification surgery in her right eye under general anesthesia. She did not have any history of systemic diseases except for controlled stage‐1 hypertension. The patient had a history of COVID‐19 infection confirmed by positive PCR 4 weeks before the operation. This patient also developed limited SCH in the inferior retina during the irrigation and aspiration phase. However, we could insert the IOL in the same theater. SCH was almost resorbed in 3 weeks. The final BCVA was 20/25. None of the cases had a history of COVID‐19 vaccination, but their disease did not involve the lungs or required hospitalization, and they fully recovered within 2 weeks.

DISCUSSION

COVID‐19 exacerbation is partly attributed to a cytokine storm initiated by increasing levels of several pro‐inflammatory cytokines. Meanwhile, significant endothelial cell injury increases vascular permeability and leakage. , Although the lungs are the primary target for overwhelming inflammation and damage, several studies reported multiorgan failure due to systemic vascular involvement. The choroid is the most densely vascularized tissue in the body. Angiotensin‐converting enzyme 2 is a well‐documented receptor for SARS‐CoV‐2 and is highly expressed in ocular vascular endothelial cells. So, in principle, choroidal and retinal vessels could be affected by COVID‐19. In fact, recent studies reported microvascular and macrovascular retinal and choroidal changes in cases with COVID‐19. , , Although such involvements for choroidal vessels are not clinically supported so far, subclinical injuries from cytokine storm to these vessels are quite possible and might be a risk factor for SCH in patients undergoing intraocular surgery during the recovery phase of COVID‐19. This assumption is partly supported by the lack of known systemic or ocular risk factors of SCH in our patients and also their recent evident infection with COVID‐19. In the same setting, we had a rate of approximately 0.03% for intraoperative SCH during phacoemulsification in the pre‐COVID‐19 era (all in patients with known risk factors, systemic risk factors include old age and arteriosclerosis, coagulation disorders, vascular hypertension, diabetes mellitus, intraoperative tachycardia, and ocular risk factors include high myopia, glaucoma, previous vitrectomy, pseudophakia, and aphakia ), further increasing our suspicion of COVID‐19 as a predisposing factor for SCH in patients mentioned above. Recent COVID‐19 infection might be a risk factor for SCH in patients undergoing cataract surgery. Although the two reported cases could not verify any cause‐and‐effect relationship, we should be vigilant about the possible association. Since COVID‐19 has the potential to make many known and unknown changes to the human body, it is wise to postpone elective surgeries for several months after infection to let the body completely recovers itself.

AUTHOR CONTRIBUTIONS

Hossein Jamali and Elham Sadeghi contributed to study design and manuscript writing; Mohammad Hossein Nowroozzadeh contributed to writing/editing the manuscript

CONFLICT OF INTEREST

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

CONSENT

Written informed consent was obtained from the cases to publish this article and any accompanying image.
  9 in total

1.  COVID-19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease?

Authors:  M F Landecho; J R Yuste; E Gándara; P Sunsundegui; J Quiroga; A B Alcaide; A García-Layana
Journal:  J Intern Med       Date:  2020-07-30       Impact factor: 8.989

2.  Retinal findings in hospitalised patients with severe COVID-19.

Authors:  Leonardo Amarante Pereira; Larissa Caroline Mansano Soares; Priscila Alves Nascimento; Luciano Rabello Netto Cirillo; Hebert Toshiaki Sakuma; Glaucia Luciano da Veiga; Fernando Luiz Afonso Fonseca; Vagner Loduca Lima; Julio Zaki Abucham-Neto
Journal:  Br J Ophthalmol       Date:  2020-10-16       Impact factor: 4.638

3.  Choroidal effusion and suprachoroidal hemorrhage during phacoemulsification: intraoperative management to prevent expulsive hemorrhage.

Authors:  Alfonso Savastano; Stanislao Rizzo; Maria Cristina Savastano; Valerio Piccirillo; Renato Forte; Sandro Sbordone; Francesco Diurno; Silvio Savastano
Journal:  Eur J Ophthalmol       Date:  2015-11-06       Impact factor: 2.597

4.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

5.  Outcomes of suprachoroidal haemorrhage drainage with and without vitrectomy: a 10-year study.

Authors:  Amreen Qureshi; Assad Jalil; David C Sousa; Niall Patton; Felipe Dhawahir-Scala; Stephen J Charles; George Turner; Tsveta Ivanova
Journal:  Eye (Lond)       Date:  2020-09-02       Impact factor: 4.456

Review 6.  COVID-19: Are we dealing with a multisystem vasculopathy in disguise of a viral infection?

Authors:  Ritwick Mondal; Durjoy Lahiri; Shramana Deb; Deebya Bandyopadhyay; Gourav Shome; Sukanya Sarkar; Sudeb R Paria; Tirthankar Guha Thakurta; Pratibha Singla; Subhash C Biswas
Journal:  J Thromb Thrombolysis       Date:  2020-10       Impact factor: 5.221

7.  COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection.

Authors:  Hanny Al-Samkari; Rebecca S Karp Leaf; Walter H Dzik; Jonathan C T Carlson; Annemarie E Fogerty; Anem Waheed; Katayoon Goodarzi; Pavan K Bendapudi; Larissa Bornikova; Shruti Gupta; David E Leaf; David J Kuter; Rachel P Rosovsky
Journal:  Blood       Date:  2020-07-23       Impact factor: 25.476

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.